Alexei E. Miroshnikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexei E. Miroshnikov has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- O. V. Lebedeva
Representative office of Sanofi-aventis group JSC (France)
5 shared publications - A. A. Khokhlov
LLC «AX CT
4 shared publications - Aleksandr Leonidovich Khokhlov
Yaroslavl State Medical University
4 shared publications - D. Yu. Grebenkin
LLC "Exacte Labs, Russia
4 shared publications - Vasily I. Kazey
Exacte Labs
3 shared publications - A. A. Khokhlov
LLC "AX CT
2 shared publications
Latest Publications
- Open Access
- 3 July 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (3) , 194-207
Socio-Psychological Aspects of Introducing Mobile Technologies into Clinical Trials
Background: High political and economic turbulence, changes in the international relations and cross-national economic ties enhance the demand for developing and launching new pharmacological treatments as a part of nationally independent health care program and import substitution policy. The number of clinical trials is growing rapidly, increasing the need for more effective solutions in organizing these trials optimizing the time, financial resources and efforts of medical personnel. The global trend of creating a new digital ecosystem in health care also raises the issues of higher patient involvement, taking into account the patient's psychological and physical barriers including the issues of personal data security. Aims: Evaluating the motivation and readiness of current clinical trials participants to switch to mobile technologies and identifying the barriers for these shifts. Method: The survey among 75 participants of clinical trials using offline self-completed questionnaire, data processing using statistical tools for data analysis. Results: Currently, 56% of respondents who are current participants of traditional medical trials would definitely agree to participate in mobile clinical trials. Compared to the consistency rate between traditional clinical trials estimated as 73%, the shift to a new format will result in 17% additional losses. The serious barrier for participation is the concerns about the security of personal information it is highly relevant for 37% of respondents and moderately relevant for 44%. The important motivating factor for the participation is the open access to personal medical data - 44% of respondents were highly interested in obtaining this data and 31% are somewhat interested. Conclusion. The results of the pilot study confirmed relatively high readiness of current participants to join mobile clinical trials and use mobile devices and solutions in future trials. However the level of readiness is unequal between different socio-demographic groups. Differentiating parameters are age, former experience of clinical trials and the skills in using digital technologies. Training programs for managers and researchers of clinical trials, provision of devices for non-users, timely technical support during the data collection and transparency in data usages can help to address key issues which slow down the peoples participation in mobile trials.
- 3 July 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (3) , 194-207
Open AccessSocio-Psychological Aspects of Introducing Mobile Technologies into Clinical Trials
Background: High political and economic turbulence, changes in the international relations and cross-national economic ties enhance the demand for developing and launching new pharmacological treatments as a part of nationally independent health care program and import substitution policy. The number of clinical trials is growing rapidly, increasing the need for more effective solutions in organizing these trials optimizing the time, financial resources and efforts of medical personnel. The global trend of creating a new digital ecosystem in health care also raises the issues of higher patient involvement, taking into account the patient's psychological and physical barriers including the issues of personal data security. Aims: Evaluating the motivation and readiness of current clinical trials participants to switch to mobile technologies and identifying the barriers for these shifts. Method: The survey among 75 participants of clinical trials using offline self-completed questionnaire, data processing using statistical tools for data analysis. Results: Currently, 56% of respondents who are current participants of traditional medical trials would definitely agree to participate in mobile clinical trials. Compared to the consistency rate between traditional clinical trials estimated as 73%, the shift to a new format will result in 17% additional losses. The serious barrier for participation is the concerns about the security of personal information it is highly relevant for 37% of respondents and moderately relevant for 44%. The important motivating factor for the participation is the open access to personal medical data - 44% of respondents were highly interested in obtaining this data and 31% are somewhat interested. Conclusion. The results of the pilot study confirmed relatively high readiness of current participants to join mobile clinical trials and use mobile devices and solutions in future trials. However the level of readiness is unequal between different socio-demographic groups. Differentiating parameters are age, former experience of clinical trials and the skills in using digital technologies. Training programs for managers and researchers of clinical trials, provision of devices for non-users, timely technical support during the data collection and transparency in data usages can help to address key issues which slow down the peoples participation in mobile trials.
- Open Access
- 28 February 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (1) , 142-153
Pharmacokinetic and Bioequivalence Study of the Two-component Drug Product "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia): Resuts and Experience with the Use of Enzymatic Hydrolysis in the Analysis of Samples
Introduction. As a part of the registration of the drug product a bioequivalence study of the fixed-dose combination "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia) compared with coadministered Ezetrol® (ezetimibe) and Crestor® (rosuvastatin) was conducted with 76 healthy volunteers. Enzymatic hydrolysis was used to evaluate the pharmacokinetics of total ezetimibe. This was the reason for the inclusion of the additional monitored parameters in the validation and analysis.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed-dose combination "Ezetimibe + rosuvastatin" (ezetimibe + rosuvastatin,tablets, 10 + 40 mg, JSC "Sanofi-aventis group", Russia) compared with coadministrated monocomponent drugs ezetimibe and rosuvastatin in fasting healthy volunteers after a single administration using the described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide during the analysis of samples.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover two-period clinical trial was conducted. During the study, blood plasma samples were taken from volunteers, the concentrations of ezetimibe (unconjugated) and total ezetimibe (ezetimibe + ezetimibe-glucuronide) and rosuvastatin in plasma samples were determined by validated HPLC-MS/MS methods. Based on the received data pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of ezetimibe (free) and rosuvastatin. Pharmacokinetic parameters of total ezetimibe were considered as secondary and were not required for the conclusion on bioequivalence. While HPLC-MS/MS analysis of incurred samples, additional control parameters for the enzymatic hydrolysis of ezetimibe-glucuronide made it possible to legitimately reject the results of inaccurate analytical batches.Conclusion. Thus, according to the criteria used in the study, the drugs are proved to be bioequivalent. The described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide have been shown to be effective.
- 28 February 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (1) , 142-153
Open AccessPharmacokinetic and Bioequivalence Study of the Two-component Drug Product "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia): Resuts and Experience with the Use of Enzymatic Hydrolysis in the Analysis of Samples
Introduction. As a part of the registration of the drug product a bioequivalence study of the fixed-dose combination "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia) compared with coadministered Ezetrol® (ezetimibe) and Crestor® (rosuvastatin) was conducted with 76 healthy volunteers. Enzymatic hydrolysis was used to evaluate the pharmacokinetics of total ezetimibe. This was the reason for the inclusion of the additional monitored parameters in the validation and analysis.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed-dose combination "Ezetimibe + rosuvastatin" (ezetimibe + rosuvastatin,tablets, 10 + 40 mg, JSC "Sanofi-aventis group", Russia) compared with coadministrated monocomponent drugs ezetimibe and rosuvastatin in fasting healthy volunteers after a single administration using the described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide during the analysis of samples.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover two-period clinical trial was conducted. During the study, blood plasma samples were taken from volunteers, the concentrations of ezetimibe (unconjugated) and total ezetimibe (ezetimibe + ezetimibe-glucuronide) and rosuvastatin in plasma samples were determined by validated HPLC-MS/MS methods. Based on the received data pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of ezetimibe (free) and rosuvastatin. Pharmacokinetic parameters of total ezetimibe were considered as secondary and were not required for the conclusion on bioequivalence. While HPLC-MS/MS analysis of incurred samples, additional control parameters for the enzymatic hydrolysis of ezetimibe-glucuronide made it possible to legitimately reject the results of inaccurate analytical batches.Conclusion. Thus, according to the criteria used in the study, the drugs are proved to be bioequivalent. The described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide have been shown to be effective.
- Open Access
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 69-77
Pharmacokinetic and bioequivalence study of Telzap® Plus fixed-dose combination compared with MikardisPlus® in healthy volunteers after single administration
Introduction. A fixed dose combination of telmisartan and hydrochlorothiazide is indicated for treatment of in the treatment of arterial hypertension. The combination of these substances causes an additive effect that helps to reduce blood pressure. A bioequivalence study of Telzap® Plus compared with MikardisPlus® was conducted with 63 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed dose combination drug product Telzap® Plus (tablets 80 mg + 12,5 mg, Zentiva KS company, Czech Republic) compared with drug products MikardisPlus® (telmisartan+hydrochlorothiazide, tablets 80 mg + 12,5 mg, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover fourperiod replicate single-center clinical trial was conducted. The concentrations of hydrochlorothiazide and telmisartan in plasma samples were determined with a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of hydrochlorothiazide and telmisartan. All 90 % confidence intervals for the estimated pharmacokinetic parameters of hydrochlorothiazide were in the range of 80–125 %, 90 % confidence intervals for telmisartan were within the bioequivalence range of 80–125 % for AUC0-72, and 79,30–126,11 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 69-77
Open AccessPharmacokinetic and bioequivalence study of Telzap® Plus fixed-dose combination compared with MikardisPlus® in healthy volunteers after single administration
Introduction. A fixed dose combination of telmisartan and hydrochlorothiazide is indicated for treatment of in the treatment of arterial hypertension. The combination of these substances causes an additive effect that helps to reduce blood pressure. A bioequivalence study of Telzap® Plus compared with MikardisPlus® was conducted with 63 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed dose combination drug product Telzap® Plus (tablets 80 mg + 12,5 mg, Zentiva KS company, Czech Republic) compared with drug products MikardisPlus® (telmisartan+hydrochlorothiazide, tablets 80 mg + 12,5 mg, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover fourperiod replicate single-center clinical trial was conducted. The concentrations of hydrochlorothiazide and telmisartan in plasma samples were determined with a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of hydrochlorothiazide and telmisartan. All 90 % confidence intervals for the estimated pharmacokinetic parameters of hydrochlorothiazide were in the range of 80–125 %, 90 % confidence intervals for telmisartan were within the bioequivalence range of 80–125 % for AUC0-72, and 79,30–126,11 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- Open Access
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 62-68
Pharmacokinetic and bioequivalence study of Telzap® in comparison with Mikardis® in healthy subjects after single administrationl
Introduction. Telmisartan is widely used in clinical practice during hypertension treatment. It is a specific angiotensin II receptor antagonist (type AT1), effective at oral intake, A bioequivalence study of Telzap® and Mikardis® was conducted with 60 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of Mikardis® (telmisartan, tablets 80 mg, Boehringer Ingelheim International GmbH, Germany) and Telzap® (telmisartan, tablets 80 mg, Zentiva KS company, Czech Republic) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period replicate single-center clinical trial was conducted. The concentrations of telmisartan in plasma samples were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of test and reference drug. All 90 % confidence intervals of were within the bioequivalence range of 80–125 % for AUC0-72 and 73,07–136,85 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 62-68
Open AccessPharmacokinetic and bioequivalence study of Telzap® in comparison with Mikardis® in healthy subjects after single administrationl
Introduction. Telmisartan is widely used in clinical practice during hypertension treatment. It is a specific angiotensin II receptor antagonist (type AT1), effective at oral intake, A bioequivalence study of Telzap® and Mikardis® was conducted with 60 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of Mikardis® (telmisartan, tablets 80 mg, Boehringer Ingelheim International GmbH, Germany) and Telzap® (telmisartan, tablets 80 mg, Zentiva KS company, Czech Republic) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period replicate single-center clinical trial was conducted. The concentrations of telmisartan in plasma samples were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of test and reference drug. All 90 % confidence intervals of were within the bioequivalence range of 80–125 % for AUC0-72 and 73,07–136,85 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- Open Access
- 1 May 2022
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 61-74
Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to take which helps to improve patient adherence to therapy. A bioequivalence study of the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi with coadministered Lozap® AM (Losartan+Amlodipine) and Crestor® (Rosuvastatin) was conducted. Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of two strengths of fixed-dose combination: 1) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 50 mg + 5 mg + 10 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 50 mg + 5 mg,) and Crestor® (rosuvastatin, tablets, 10 mg) in fasting healthy volunteers after a single administration; 2) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 100 mg + 5 mg + 20 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 100 mg + 5 mg) and Crestor® (rosuvastatin, tablets, 20 mg) in fasting healthy volunteers 18–45 years old after a single dose. Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period clinical trial was conducted for each strengths of fixed-dose combination. The concentrations of losartan, amlodipine and rosuvastatin in blood plasma samples obtained from volunteers were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Сmax, AUC0-72 (for amlodipine) and AUC0-t (for losartan and rosuvastatin) were calculated. Results and discussion. Based on the results of statistical and pharmacokinetic analysis, it was shown that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of losartan, amlodipine and rosuvastatin. 90 % CI were in the acceptable range for Сmax (of amlodipine), AUC0-72 (of amlodipine) and AUC0-t (of losartan and rosuvastatin). 90 % CI for Сmax of losartan and rosuvastatin were in the acceptable extended calculated range according to the protocol. Conclusion. Thus, according to the criteria used in the studies, the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi are proved to be bioequivalent in comparison with coadministered Lozap® AM and Crestor®.
- 1 May 2022
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 61-74
Open AccessBioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to take which helps to improve patient adherence to therapy. A bioequivalence study of the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi with coadministered Lozap® AM (Losartan+Amlodipine) and Crestor® (Rosuvastatin) was conducted. Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of two strengths of fixed-dose combination: 1) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 50 mg + 5 mg + 10 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 50 mg + 5 mg,) and Crestor® (rosuvastatin, tablets, 10 mg) in fasting healthy volunteers after a single administration; 2) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 100 mg + 5 mg + 20 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 100 mg + 5 mg) and Crestor® (rosuvastatin, tablets, 20 mg) in fasting healthy volunteers 18–45 years old after a single dose. Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period clinical trial was conducted for each strengths of fixed-dose combination. The concentrations of losartan, amlodipine and rosuvastatin in blood plasma samples obtained from volunteers were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Сmax, AUC0-72 (for amlodipine) and AUC0-t (for losartan and rosuvastatin) were calculated. Results and discussion. Based on the results of statistical and pharmacokinetic analysis, it was shown that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of losartan, amlodipine and rosuvastatin. 90 % CI were in the acceptable range for Сmax (of amlodipine), AUC0-72 (of amlodipine) and AUC0-t (of losartan and rosuvastatin). 90 % CI for Сmax of losartan and rosuvastatin were in the acceptable extended calculated range according to the protocol. Conclusion. Thus, according to the criteria used in the studies, the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi are proved to be bioequivalent in comparison with coadministered Lozap® AM and Crestor®.
- Open Access
- 26 November 2020
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 9 (4) , 155-163
Pharmacokinetic and Bioequivalence Study of Telzap AM® (Telmisartan/amlodipine Fixed-dose Combination) and Coadministered Mikardis® (Telmisartan) and Norvask® (Amlodipine) in Healthy Subjects
Introduction. A fixed dose combination of telmisartan and amlodipine is widely used in clinical practice during hypertension treatment. Combination of telmisartan and amlodipine demonstrates potentiating synergistic effect on blood pressure decrease. A bioequivalence study of Telzap® AM with coadministered Mikardis® and Norvask® was conducted with 60 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed dose combination drug product Telzap® AM (telmisartan + amlodipine, tablets, 80 + 10 mg, Zentiva ks company, Czech Republic) and coadministrated monocomponent drug products Mikardis® (telmisartan, tablets 80 mg, Beringer Ingelheim International GmbH, Germany) and Norvask® [amlodipine, tablets 10 mg, Pfizer HCP Corporation (USA), Russia] in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period replicate clinical trial was conducted. The concentrations of amlodipine and telmisartan in plasma samples were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of amlodipine and telmisartan. All 90 % confidence intervals for the estimated pharmacokinetic parameters of amlodipine were in the range of 80–125 %, 90 % confidence intervals for telmisartan were within the bioequivalence range of 80–125 % for AUC0-72, and 76.73–130.32 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- 26 November 2020
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 9 (4) , 155-163
Open AccessPharmacokinetic and Bioequivalence Study of Telzap AM® (Telmisartan/amlodipine Fixed-dose Combination) and Coadministered Mikardis® (Telmisartan) and Norvask® (Amlodipine) in Healthy Subjects
Introduction. A fixed dose combination of telmisartan and amlodipine is widely used in clinical practice during hypertension treatment. Combination of telmisartan and amlodipine demonstrates potentiating synergistic effect on blood pressure decrease. A bioequivalence study of Telzap® AM with coadministered Mikardis® and Norvask® was conducted with 60 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed dose combination drug product Telzap® AM (telmisartan + amlodipine, tablets, 80 + 10 mg, Zentiva ks company, Czech Republic) and coadministrated monocomponent drug products Mikardis® (telmisartan, tablets 80 mg, Beringer Ingelheim International GmbH, Germany) and Norvask® [amlodipine, tablets 10 mg, Pfizer HCP Corporation (USA), Russia] in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period replicate clinical trial was conducted. The concentrations of amlodipine and telmisartan in plasma samples were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of amlodipine and telmisartan. All 90 % confidence intervals for the estimated pharmacokinetic parameters of amlodipine were in the range of 80–125 %, 90 % confidence intervals for telmisartan were within the bioequivalence range of 80–125 % for AUC0-72, and 76.73–130.32 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- Open Access
- 13 July 2020
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 5 (3) , 13-23
Pharmacogenetic Aspects of Type 2 Diabetes Treatment
In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G allele of KCNJ11 rs5218 gene polymorphism are associated with the response to IDPP-4 therapy; the presence of KCNJ11 gene rs5210 polymorphism A allele is a predictor of poor response. The effect of rs7903146 polymorphism of TCF7L2 gene was evaluated on the response to treatment of patients taking linagliptin. Linagliptin significantly reduced HbA1c levels for all three rs7903146 genotypes (CC: –0.82 %; CT: –0.77 %; TT: –0.57 %). A significantly smaller effect of therapy was observed with the genotype with ТТ. The rs622342 polymorphism of SLC22A1 gene was studied in effectiveness of metformin. The researches demonstrated that carriers of variant AA had an average decrease of HbA1c of 0.53 %, heterozygous – decrease of 0.32 %, and carriers of a minor variant of SS had an increase of 0.2 % in the level of HbA1c. A significant effect of CYP2C9 polymorphisms on the pharmacokinetic parameters of PSM was noted. When studying the kinetics of glibenclamide, it was found that carriage of the allele *2 significantly reduces glibenclamide metabolism: homozygous carriers had clearance 90 % lower than homozygous carriers of the wild variant. The studies confirmed the association of the allelic variants of Thr394Thr and Gly482Ser of PPARγ gene with higher efficacy of the rosiglitazone. The data obtained from the analysis of the association of the Pro12Ala polymorphism of PPARγ gene and the response to therapy is contradictory. Thus the personalized approach, based on the knowledge of polymorphism options, will allow choosing the most effective drug with transparent kinetics for each individual patient.
- 13 July 2020
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 5 (3) , 13-23
Open AccessPharmacogenetic Aspects of Type 2 Diabetes Treatment
In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G allele of KCNJ11 rs5218 gene polymorphism are associated with the response to IDPP-4 therapy; the presence of KCNJ11 gene rs5210 polymorphism A allele is a predictor of poor response. The effect of rs7903146 polymorphism of TCF7L2 gene was evaluated on the response to treatment of patients taking linagliptin. Linagliptin significantly reduced HbA1c levels for all three rs7903146 genotypes (CC: –0.82 %; CT: –0.77 %; TT: –0.57 %). A significantly smaller effect of therapy was observed with the genotype with ТТ. The rs622342 polymorphism of SLC22A1 gene was studied in effectiveness of metformin. The researches demonstrated that carriers of variant AA had an average decrease of HbA1c of 0.53 %, heterozygous – decrease of 0.32 %, and carriers of a minor variant of SS had an increase of 0.2 % in the level of HbA1c. A significant effect of CYP2C9 polymorphisms on the pharmacokinetic parameters of PSM was noted. When studying the kinetics of glibenclamide, it was found that carriage of the allele *2 significantly reduces glibenclamide metabolism: homozygous carriers had clearance 90 % lower than homozygous carriers of the wild variant. The studies confirmed the association of the allelic variants of Thr394Thr and Gly482Ser of PPARγ gene with higher efficacy of the rosiglitazone. The data obtained from the analysis of the association of the Pro12Ala polymorphism of PPARγ gene and the response to therapy is contradictory. Thus the personalized approach, based on the knowledge of polymorphism options, will allow choosing the most effective drug with transparent kinetics for each individual patient.
- Open Access
- 5 September 2019
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 8 (3) , 101-106
lanning and Evaluation of Bioequivalence Studies of Telmisartan Generic Drug Products
Introduction. Telmisartan is a modern antihypertensive drug, from the group of angiotensin II receptor antagonists, which, recently, has been the purpose of the development and registration of generic drug. The pharmaceutical development of telmisartan generics and their evaluation in bioequivalence studies is complicated by many factors that influence the results of comparison with the reference drug. Therefore, it is relevant to study these factors for the proper planning of studies and for evaluating their results from the generic drugs of telmisartan.Aim. The aim of the study is to identify the key factors that should be considered in planning and evaluation of bioequivalence studies of telmisartan’s generics.Materials and methods. To identify the key factors influencing the planning and evaluation of studies of telmisartan generics, a retrospective analysis of the results of seven telmisartan studies was conducted. Calculated pharmacokinetic parameters Cmax, AUC0-t, tmax; their average values; the values of intraindividual variability for each study and the average of the coefficients of intraindividual variability obtained.Results and discussion. The results of the study demonstrated that the drugs of telmisartan are highly variable, there are sex differences in the pharmacokinetics of telmisartan. According to the averaged values of the concentrations and pharmacokinetic profiles of telmisartan, the following areas were determined: the area of maximum exposure of telmisartan, the duration and schedule of blood sampling, to obtain the optimal pharmacokinetic profile. The most optimal method for the determination of telmisartan is HPLC MS/MS with a lower limit of quantification in the range of 0.5–3 ng/ml. The upper limit of the 90% confidence interval was calculated for the pooled average of the coefficients of intraindividual variability obtained in the considered studies.Conclusion. Recommendations were developed for planning and evaluating bioequivalence studies of generic telmisartan preparations. It is necessary to plan bioequivalence studies with replicated design in three or four periods, with two crossovers, with two sequences of drug intake. To assess the pharmacokinetics of telmisartan one should use the data on its exposure given in the article. When determining the sample size, one should be guided by the upper limit of the confidence interval of the averaged values of the coefficient of intra-individual variability Cmax of telmisartan (45%). Evaluation of results should be carried out taking into account the possibility of scaling bioequivalence limits for the Cmax. The bioequivalence limit for the AUC0-t parameter should remain in the range of 80.00–125.00%, as well as the ratio of geometric means for both parameters.
- 5 September 2019
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 8 (3) , 101-106
Open Accesslanning and Evaluation of Bioequivalence Studies of Telmisartan Generic Drug Products
Introduction. Telmisartan is a modern antihypertensive drug, from the group of angiotensin II receptor antagonists, which, recently, has been the purpose of the development and registration of generic drug. The pharmaceutical development of telmisartan generics and their evaluation in bioequivalence studies is complicated by many factors that influence the results of comparison with the reference drug. Therefore, it is relevant to study these factors for the proper planning of studies and for evaluating their results from the generic drugs of telmisartan.Aim. The aim of the study is to identify the key factors that should be considered in planning and evaluation of bioequivalence studies of telmisartan’s generics.Materials and methods. To identify the key factors influencing the planning and evaluation of studies of telmisartan generics, a retrospective analysis of the results of seven telmisartan studies was conducted. Calculated pharmacokinetic parameters Cmax, AUC0-t, tmax; their average values; the values of intraindividual variability for each study and the average of the coefficients of intraindividual variability obtained.Results and discussion. The results of the study demonstrated that the drugs of telmisartan are highly variable, there are sex differences in the pharmacokinetics of telmisartan. According to the averaged values of the concentrations and pharmacokinetic profiles of telmisartan, the following areas were determined: the area of maximum exposure of telmisartan, the duration and schedule of blood sampling, to obtain the optimal pharmacokinetic profile. The most optimal method for the determination of telmisartan is HPLC MS/MS with a lower limit of quantification in the range of 0.5–3 ng/ml. The upper limit of the 90% confidence interval was calculated for the pooled average of the coefficients of intraindividual variability obtained in the considered studies.Conclusion. Recommendations were developed for planning and evaluating bioequivalence studies of generic telmisartan preparations. It is necessary to plan bioequivalence studies with replicated design in three or four periods, with two crossovers, with two sequences of drug intake. To assess the pharmacokinetics of telmisartan one should use the data on its exposure given in the article. When determining the sample size, one should be guided by the upper limit of the confidence interval of the averaged values of the coefficient of intra-individual variability Cmax of telmisartan (45%). Evaluation of results should be carried out taking into account the possibility of scaling bioequivalence limits for the Cmax. The bioequivalence limit for the AUC0-t parameter should remain in the range of 80.00–125.00%, as well as the ratio of geometric means for both parameters.
- Open Access
- 20 December 2018
- Published by SCEEMP in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
- Vol. 8 (4)
Planning and Evaluation of Bioequivalence Studies of Enalapril Products
- 20 December 2018
- Published by SCEEMP in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
- Vol. 8 (4)
Open AccessPlanning and Evaluation of Bioequivalence Studies of Enalapril Products
- 1 September 2017
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 51 (6) , 504-507
Quantitative Determination of Mycophenolic Acid in Human Blood Plasma by High-Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection
- 1 September 2017
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 51 (6) , 504-507
Quantitative Determination of Mycophenolic Acid in Human Blood Plasma by High-Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection